The trial would be held across 10 sites and would cover 920 children -- 460 each in the age groups of 12-17 and 2-11 -- according to official sources.
India’s pool of Covid-19 vaccines is set to receive a shot in the arm with two more approaching the apex drug regulator for approval.
Covovax will be a two-dose vaccine and the price will be decided at the time of launch, he added.
The SII applied to the Drugs Controller General of India on Monday seeking permission for conducting a trial of Covovax on 920 children, 460 each in the 12-17 and 2-11 age groups, at 10 sites.
Earlier, Novavax had said that its vaccine has an efficacy of 90.4% in preventing infection and 100% efficacy against moderate to severe disease.
The development and commercialisation pact between Novavax and SII excludes major upper-middle and high-income countries, for which Novavax continues to retain rights.